AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
Zacks Investment Research | Oct 02, 2019 07:05AM ET
AstraZeneca plc (NYSE:AZN) announced that the FDA has given a complete response letter to its new drug application (NDA) looking for approval of its investigational triple combination therapy, PT010 for chronic obstructive pulmonary disease (COPD).
PT010 is a combination of budesonide, an ICS with glycopyrronium, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a long-acting beta-agonists (LABA) therapy. PT010 can be delivered using AstraZeneca’s Aerosphere Delivery Technology.
Japan’s Ministry of Health, Labour and Welfare approved PT010 in June by the trade name of Breztri Aerosphere to relieve symptoms of COPD. The candidate is also under review in the EU and China.
The NDA was based on data from the KRONOS study, which compared PT010 to AstraZeneca’s own dual-combination therapies — Bevespi Aerosphere, Symbicort Turbuhaler, and PT009 — in COPD indication. AstraZeneca said that it will meet with the FDA to discuss the next steps including submission of data from another study — ETHOS — on PT010 for review. ETHOS data was not included in the NDA as the study was incomplete at that time. Last month, AstraZeneca announced that the ETHOS study, which evaluated PT010 in patients with moderate-to-very-severe COPD, met the primary endpoint. In the study, Breztri Aerosphere showed a statistically-significant reduction in the rate of moderate or severe exacerbations — the primary endpoint — at both standard and low budesonide doses compared with Bevespi and PT009 in the abovementioned COPD patients who have had a history of exacerbation(s) in the previous year.
We remind investors that Glaxo (NYSE:GSK) also markets a once-daily, single inhaler triple combination therapy, Trelegy Ellipta for COPD. Trelegy Ellipta is a combination of fluticasone furoate — an ICS, umeclidinium — a LAMA and vilanterol — a LABA therapy. Trelegy Ellipta is delivered in Glaxo’s Ellipta dry powder inhaler. Theravance Biopharma, Inc. (NASDAQ:TBPH) has an economic interest in Trelegy Ellipta and earns royalties on its sales.
In a separate press release, AstraZeneca announced that it is divesting global rights to its acid reflux medicine, Losec (omeprazole) and other medicines containing omeprazole to Germany’s pharma company, Cheplapharm. The divestment of the global commercial rights, excluding China, Japan, the United States and Mexico, of these mature medicines, will allow the company to focus on three main therapy areas - Oncology; Cardiovascular, Renal and Metabolism; and Respiratory. For the deal, AstraZeneca will get a payment of approximately $243 million from Cheplapharm on closure, plus sales-contingent milestones of up to $33 million in 2021 and 2022. Earlier, AstraZeneca had divested the commercial rights to Losec and other omeprazole medicines in the United States, Japan and Mexico.
Get The News You Want
Recently, at the European Society of Medical Oncology (ESMO) congress in Barcelona, Spain, AstraZeneca and partner Merck (NYSE:MRK) presented detailed data from two late-stage label expansion studies on their PARP inhibitor, Lynparza. Data from the PAOLA-1 study showed that Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.